Sex: F
Vaccine: RAB
Symptoms: Inappropriate schedule of product administration, Medication error, No adverse event
Clinical narrative: The patient was vaccinated with third dose of RabAvert vaccine on day 14 instead on day 21; Case reference number US-BN-2022-001380 is a spontaneous case report initially received on 23-Jun-2022 from a health care professional (reference number: USBAV22-0402) and concerns a *32-year-old female patient*.  The patient *had no medical history and was not taking any concomitant medications.*  On an unknown date, the patient was vaccinated with the first dose of RabAvert (Rabies Virus (Inactivated, Strain Flury LEP); batch number unknown) at unknown dose or route of administration for unknown indication.  On an unknown date, unknown amount of time after the first dose, the patient was vaccinated with the second dose of RabAvert (batch number unknown) at unknown dose or route of administration for unknown indication.  On *23-Jun-2022*, 14 days after the first dose, the patient was vaccinated with the third dose of RabAvert (batch number: *YRBA841B, expiration date: 28-Feb-2024*) at unknown dose, *intramuscularly, in the left deltoid region*, for unknown indication (explicitly coded as 'inappropriate schedule of vaccine administered').  *It was confirmed that the patient did not experience adverse event.*  Additional information received from Bavarian Nordic on 24-Jun-2022 included local case ID.  All follow-up information is blended into the case narrative above, with the latest information presented between asterisks (*).  Follow up information was received from other health professional (nurse) on 28-Jul-2022: New information included date of administration, batch number, expiration date, anatomical location and site of administration for the third dose of RabAvert; patient's details.; Reporter's Comments: A 32-year-old female patient was vaccinated with the third dose of RabAvert for unknown indication, as reported, on the day 14 after the first dose, which is considered as inappropriate schedule of product administration. No associated adverse events have been reported with the reported medication error. Inappropriate schedule of product administration is considered as listed per company convention. The patient had no medical history and was not taking any concomitant medications. Inappropriate schedule of product administration has been considered as not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: A 32-year-old female patient was vaccinated with the third dose of RabAvert for unknown indication, as reported, on the day 14 after the first dose, which is considered as inappropriate schedule of product administration. No associated adverse events have been reported with the reported medication error. Inappropriate schedule of product administration is considered as listed per company convention. The patient had no medical history and was not taking any concomitant medications. Inappropriate schedule of product administration has been considered as not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.